VA-REGULA
MWC attracts tens of thousands of visitors, including representatives of mobile operators, device manufacturers, technology providers, vendors, and content owners. To ensure everyone's safety, the GSMA has traditionally conducted thorough registration and ID validation processes for each attendee.
For many years, the ID validation process was done on-site at the venue, which caused queues and long wait times. With the advent of the pandemic in 2020, and attendance now regularly exceeding 100,000, the GSMA had to find a contactless solution to remove the need to have attendees wait in large numbers to collect badges and have their ID validated. To address these issues and improve the efficiency of the registration process, the GSMA decided to make it totally remote and digital, so that all attendees could swiftly get access to the venue through the entry gates. Any solution would also need to enable quick and efficient international document recognition, because attendees come from all over the world.
To achieve their goal, the GSMA ran an extensive competitive tender process to find the best technology solution. Ultimately, they chose a complete, single-vendor solution by Regula which includes Regula Document Reader SDK and Regula Face SDK. Natively integrated, these solutions facilitate a smooth customer journey and rapid onboarding through seamless and secure identity verification, eliminating the possibility of fraud.
Having successfully piloted Regula products during MWC Barcelona 2021, the GSMA fully transitioned to digital visitor registration and ID validation. After several years of collaboration, this long-term partnership led to a significant enhancement of the visitor registration process, enabling a fast and convenient user experience. Now, Regula Document Reader SDK and Regula Face SDK are easily integrated into the MWC’s existing registration platform for full-fledged production use.
Now, as part of the registration process, an MWC visitor simply uploads their ID on the official website. The identity document is automatically scanned by Regula Document Reader SDK. The solution instantly recognizes the document type, reads its data, and verifies its authenticity with multiple cross-checks. Not only does it streamline the verification process (checks are completed in seconds), but it also minimizes the chance of missing compromised IDs.
Further, an MWC attendee has the opportunity to provide their selfie, which is rapidly captured by Regula Face SDK for user verification.
With the industry’s largest and most comprehensive identity document template database, which contains over 13,600 templates from 249 countries and territories, Regula supports the verification of nearly any identity document from any part of the world. Taking into account MWC attendees’ geographical spread, this ability significantly facilitates the registration process.
With Regula’s complete IDV solution, the GSMA managed to create a custom, smooth, and seamless registration experience for all MWC attendees. During the Barcelona event in 2024, Regula solutions helped to efficiently validate more than 100,000 visitors – all of them registered online beforehand, so there was no need to queue at the venue.
"Our collaboration with GSMA for MWC highlights the power of digital transformation in handling large-scale international events. By integrating our advanced ID verification technologies, not only did we enhance the security and efficiency of the registration process, but also ensured a seamless experience for attendees," says Ihar Kliashchou, Chief Technology Officer at Regula.
“The digital identity verification process has revolutionized the visitor experience, allowing more than 100,000 individuals to register and access the world’s leading connectivity event swiftly, safely, and without interruption," states Xavi Casals, Director of Technology, Innovation & Customer Experience at GSMA.
For more details on the business case, please visit the Regula website.
About GSMA
The GSMA is a global organisation unifying the mobile ecosystem to discover, develop and deliver innovation foundational to positive business environments and societal change. Our vision is to unlock the full power of connectivity so that people, industry and society thrive. Representing mobile operators and organisations across the mobile ecosystem and adjacent industries, the GSMA delivers for its members across three broad pillars: Connectivity for Good, Industry Solutions and Events.
Find out more at gsma.com.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security or speed. Regula was repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240514134027/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Crown Bioscience Expands US Presence with New Model Development Center in Kannapolis, North Carolina17.9.2025 14:30:00 CEST | Press release
Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, today announced the opening of a state-of-the-art model development center in Kannapolis, North Carolina. This strategic investment expands the company’s operations and enhances its ability to deliver advanced preclinical oncology models, including patient-derived xenografts (PDX), PDX warm models, PDX-derived organoids (PDXO), and patient-derived organoids (PDO), to meet the evolving needs of pharmaceutical and biotechnology companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917864004/en/ Crown Bioscience celebrate the official ribbon-cutting ceremony for the company’s new Kannapolis, North Carolina facility, marking an expansion of US oncology model development and preclinical CRO services. The new facility strengthens Crown Bioscience’s US-based capabil
SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment17.9.2025 14:00:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced the launch of a new brand, “Hada no Aozora Clinic”, scheduled to open in Tokyo on October 1, 2025. This clinic will adopt a hybrid dermatology model that integrates insurance-covered general dermatology and private-pay aesthetic treatments, advancing SBC’s multi-brand strategy in the rapidly expanding aesthetic medicine market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917897380/en/ SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment As life expectancy continues to rise and demographic aging accelerates, more people are seeking treatments that help them maintain both well-being and a youthful appearance over a longer lifespan. Within this environment, aesth
Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board17.9.2025 14:00:00 CEST | Press release
IND clearance marks second study accepted for RLS-1496, a first-in-class disease-modifying selective GPX4 modulator targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases and conditions associated with the biological aging process through ferroptosis Results from first RLS-1496 study in patients with psoriasis, atopic dermatitis, and skin aging are expected in Q4 2025; the actinic keratosis Phase 1b/2a study will begin in Q4 2025 Rubedo Clinical Advisory Board expands to include globally renowned dermatologist and immunologist Emma Guttman-Yassky, MD, PhD., Waldman Professor of Dermatology and Immunology and Health System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that the U.S
New Study Finds That Using Masimo Technologies to Continuously Monitor General Floor Patients Reduces Costs17.9.2025 14:00:00 CEST | Press release
Universal Surveillance Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ – Repeatedly Shown to Improve Patient Outcomes and Save Lives – Also Projected to Yield Significant Cost Savings Masimo (NASDAQ: MASI) today announced the findings of a study published in the Journal of Patient Safety in which Dr. George Blike and colleagues at Dartmouth-Hitchcock Medical Center in New Hampshire demonstrated that use of Masimo technologies to continuously monitor general floor patients can yield significant cost savings.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917266545/en/ Continuous Patient Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ In prior studies, the clinical outcome benefits of continuously monitoring patients using Masimo SET® and Patient SafetyNet™ have been shown to include lower mortality, improved resuscitative outcomes, and fewer rapid response team activations and transfers
Merck to Present New Data Highlighting Durable Effects of MAVENCLAD® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 202517.9.2025 14:00:00 CEST | Press release
Four-year data show nearly 9 in 10 RMS patients remained free from progression independent of relapse activity (PIRA)Results highlight the potential of MAVENCLAD to reduce neurodegeneration and neuroinflammation beyond established clinical efficacy outcomes in RMSEvidence suggests that MAVENCLAD effectiveness could be driven by peripheral and central effects without requiring continuous immunosuppression Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of over 30 abstracts from its multiple sclerosis (MS) portfolio. New four-year data from two large Phase 4 studies highlight the long-term efficacy, favorable disability outcomes and durable impact of MAVENCLAD® (cladribine tablets) in people living with relapsing multiple sclerosis (RMS). These findings are to be presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held September 24-26 in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom